The Resilience Paradox: Chronic Metabolic Adaptation as a Predictor of Delayed Iatrogenic Collapse in Geriatric Oncology

Background: Geriatric oncology faces a paradox: some elderly patients with significant comorbidity exhibit unexpectedly high tolerance to aggressive anticancer therapies, yet later experience severe or fatal complications from minor medical interventions. The Hypothesis: We propose that chronic, low-grade intoxication (e.g., from ethanol) induces a state of systemic pathological crosstolerance. This state is mediated by persistent upregulation of detoxification systems (CYP2E1, ALDH, GST), stress-response pathways, and anti-apoptotic programs. While clinically manifesting as reduced acute toxicity, this adaptation 1 progressively depletes reparative and homeostatic reserves. Upon completion of oncologic treatment, subsequent routine stressors (surgery, infection, new drugs) can trigger a disproportionate systemic failure due to this exhausted adaptive capacity. Implications of the Hypothesis: Counterintuitively, apparent "excellent tolerance" to toxic therapy could serve as a biomarker of high long-term iatrogenic risk. Identifying patients with this metabolic-adaptation phenotype (e.g., via CYP2E1 activity or oxidative stress markers) and implementing "reservepreservation" clinical algorithms could reduce delayed noncancer mortality in elderly survivors.